Fuller & Thaler Asset Management
LAB icon

Fuller & Thaler Asset Management’s Standard BioTools LAB Stock Holding History

Fuller & Thaler Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-223,511
Closed -$2.75M – 484
2019
Q2 		$2.75M Sell
223,511
-1,280
-0.6% -$16.3K 0.03% 254
2019
Q1 		$2.99M Buy
224,791
+3,700
+2% +$39K 0.04% 236
2018
Q4 		$1.91M Buy
221,091
+4,030
+2% +$31.4K 0.03% 268
2018
Q3 		$1.63M Hold
217,061
– – 0.02% 318
2018
Q2 		$1.29M Hold
217,061
– – 0.01% 320
2018
Q1 		$1.27M Sell
217,061
-16,700
-7% -$110K 0.01% 308
2017
Q4 		$1.38M Sell
233,761
-71,400
-23% -$391K 0.02% 294
2017
Q3 		$1.54M Buy
305,161
+22,700
+8% +$95.4K 0.02% 261
2017
Q2 		$1.14M Sell
282,461
-900
-0.3% -$4.27K 0.01% 274
2017
Q1 		$1.61M Buy
283,361
+110,800
+64% +$702K 0.02% 235
2016
Q4 		$1.26M Buy
+172,561
New +$1.08M 0.02% 236

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fuller & Thaler Asset Management's LAB Position: Q3 2019 in Review

Fuller & Thaler Asset Management sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 223,511 shares — an estimated $2.75M sold.

Fuller & Thaler Asset Management first reported a position in LAB in Q4 2016 and held it in 11 quarters. The position peaked at $2.99M in Q1 2019. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

  • Fuller & Thaler Asset Management reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 223,511 Standard BioTools shares in Q3 2019, an estimated $2.75M.
  • Fuller & Thaler Asset Management first reported a position in Standard BioTools in Q4 2016 and held it in 11 quarters.
  • Fuller & Thaler Asset Management's Standard BioTools position peaked at $2.99M in Q1 2019.
  • 125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.